Max
04-27-2004, 10:44 AM
Pain Therapeutics to Present Neuropathic Pain Data at Scientific Meeting
SOUTH SAN FRANCISCO, Calif., April 27 /PRNewswire-FirstCall/ -- Pain
Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today
announced positive pre-clinical data on a novel treatment for neuropathic
pain. The Company will present its pre-clinical data at the Scientific
Meeting of the American and Canadian Pain Societies on Friday, May 7, 2004 in
Vancouver, Canada.
Pain Therapeutics' new data opens up the possibility of using its
technology to treat neuropathic pain, a chronic condition that affects 2 to 3
million Americans and a new area of focus for the Company.
"We are excited about the possibility of using our novel technology in the
area of neuropathic pain," said Remi Barbier, Pain Therapeutics' president and
chief executive officer. "Moderate-to-severe neuropathic pain is typically
poorly managed by existing drugs, is often under-diagnosed and affects a large
patient population. We believe a novel drug that provides effective pain
relief would bring significant advantages for patients who endure this chronic
condition."
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-27-2004/0002160465&EDATE
SOUTH SAN FRANCISCO, Calif., April 27 /PRNewswire-FirstCall/ -- Pain
Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today
announced positive pre-clinical data on a novel treatment for neuropathic
pain. The Company will present its pre-clinical data at the Scientific
Meeting of the American and Canadian Pain Societies on Friday, May 7, 2004 in
Vancouver, Canada.
Pain Therapeutics' new data opens up the possibility of using its
technology to treat neuropathic pain, a chronic condition that affects 2 to 3
million Americans and a new area of focus for the Company.
"We are excited about the possibility of using our novel technology in the
area of neuropathic pain," said Remi Barbier, Pain Therapeutics' president and
chief executive officer. "Moderate-to-severe neuropathic pain is typically
poorly managed by existing drugs, is often under-diagnosed and affects a large
patient population. We believe a novel drug that provides effective pain
relief would bring significant advantages for patients who endure this chronic
condition."
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-27-2004/0002160465&EDATE